Quarterly ResultMay 15, 2026, 08:12 AM
Enveric Biosciences Q1 Net Loss $(1.63M); Raises $4.5M in April PP
AI Summary
Enveric Biosciences reported a net loss of $(1.63) million for the first quarter of 2026, an improvement compared to the $(2.18) million loss in the same period last year. Despite the reduced loss, the company continues to face substantial doubt about its ability to continue as a going concern due to accumulated deficits and ongoing operating cash outflows. To address liquidity concerns, Enveric successfully raised approximately $4.5 million in net proceeds from a private placement in April 2026, supplemented by $1.5 million from warrant exercises, significantly bolstering its cash position.
Key Highlights
- Reported a net loss of $(1,633,473) for Q1 2026, an improvement from $(2,184,966) in Q1 2025.
- Operating cash outflows for the three months ended March 31, 2026, were $(2,256,839).
- Accumulated deficit reached $116,479,965 as of March 31, 2026.
- Cash balance stood at $4,908,769 as of March 31, 2026.
- Total current liabilities decreased to $460,676 from $918,400 at December 31, 2025.
- Raised approximately $4.5 million in net proceeds from a private placement in April 2026.
- Received approximately $1.5 million from the exercise of Series G and H warrants in April 2026.
- Issued 497,200 shares for $1,291,038 net cash via ATM Agreement during Q1 2026.
Price Impact
More from ENVB